GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » EPS without NRI

CGEM (Cullinan Therapeutics) EPS without NRI : $-2.84 (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics EPS without NRI?

Cullinan Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2024 was $-0.69. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.84.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -39.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -23.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cullinan Therapeutics's EPS without NRI or its related term are showing as below:

CGEM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39   Med: -21.3   Max: -7.1
Current: -39

During the past 6 years, Cullinan Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -7.10% per year. The lowest was -39.00% per year. And the median was -21.30% per year.

CGEM's 3-Year EPS without NRI Growth Rate is ranked worse than
86.52% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs CGEM: -39.00

Cullinan Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.84.

Cullinan Therapeutics's EPS (Basic) for the three months ended in Sep. 2024 was $-0.69. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.84.


Cullinan Therapeutics EPS without NRI Historical Data

The historical data trend for Cullinan Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics EPS without NRI Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -1.07 -1.37 -1.52 -1.90 -3.68

Cullinan Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.90 -0.54 -0.86 -0.75 -0.69

Competitive Comparison of Cullinan Therapeutics's EPS without NRI

For the Biotechnology subindustry, Cullinan Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cullinan Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cullinan Therapeutics's PE Ratio without NRI falls into.



Cullinan Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cullinan Therapeutics  (NAS:CGEM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cullinan Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, Suite 1350, Cambridge, MA, USA, 02142
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Executives
Jennifer Michaelson officer: See Remarks C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Savill Corrine officer: Acting Chief Business Officer C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Nadim Ahmed director, officer: President and CEO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer officer: Chief Legal Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones officer: Chief Medical Officer ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio officer: Chief Financial Officer C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan director C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2 10 percent owner 74 GRAND RUE, LUXEMBURG N4 L-1660
F2 Bioscience I 2017 Ltd 10 percent owner 8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin director ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104